---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-049994"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2024-12-13T23:59:59+00:00"
generated_at: "2026-05-29T03:45:03.934567+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma appoints Rahul Singhvi as director, replacing Rosemary Mazanet

## Summary
- Dr. Rosemary Mazanet resigned from board effective upon appointment of new independent director; not due to disagreement.
- Dr. Rahul Singhvi appointed director effective Dec 10, 2024; will serve on audit committee, chair compensation and nominating/corporate governance committees.
- Singhvi is cofounder of Resilience, former CEO of Novavax (NVAX), former COO of Takeda's Vaccine business.
- Singhvi receives $50K annual cash fee and $50K in RSUs vesting over three years under 2023 Equity Incentive Plan.

## SEC filing metadata
- accession: 0001493152-24-049994
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2024-12-13T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315224049994/0001493152-24-049994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315224049994/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-049994
- JSON: https://secwatch.observer/filing/0001493152-24-049994.json
- Plain text: https://secwatch.observer/filing/0001493152-24-049994.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.